PA Medical News about Hodgkin lymphoma

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Use of Antiemetic Agents in Acute Gastroenteritis

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Efficacy of the BEACOPP regimen in refractory and relapsed Hodgkin lymphoma
Leukemia and Lymphoma, 11/04/09

Cavalieri E et al. – BEACOPP is an effective regimen for both refractory/relapsed patients with HL after first–line treatment (Group A) and for patients relapsing after a PBSCT (Group B) with a 3–year probability of overall survival, progression–free survival, and cumulative incidence of relapse of 90, 50, and 33.3% in Group A, and 61, 31, and 37.5% in Group B, respectively.